Skip to main content

Hepatotoxicity of Alogliptin

This is a preview of subscription content, access via your institution.


  1. 1.

    Scheen AJ. Pharmacokinetics in patients with chronic liver disease and hepatic safety of incretin-based therapies for the management of type 2 diabetes mellitus. Clin Pharmacokinet. 2014 [Epub ahead of print].

  2. 2.

    Scott LJ. Alogliptin: a review of its use in the management of type 2 diabetes mellitus. Drugs. 2010;70(15):2051–72.

    PubMed  Article  CAS  Google Scholar 

  3. 3.

    Food and Drug Administration. Alogliptin, “Other Reviews”. Accessed 18 Aug 2014.

  4. 4.

    European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP) assessment report. Vipidia (alogliptin). 2013. Accessed 18 Aug 2014.

  5. 5.

    Food and Drug Administration. Approved Drug Products. Alogliptin (2013). Accessed 18 Aug 2014.

  6. 6.

    European Medicines Agency. Alogliptin product characteristics. Accessed 18 Aug 2014.

  7. 7.

    Food and Drug Administration. Alogliptin Medical Review. Accessed 18 Aug 2014.

  8. 8.

    White WB, Cannon CP, Heller SR, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013;369:1327–35.

    PubMed  Article  CAS  Google Scholar 

  9. 9.

    Food and Drug Administration. Guidance for Industry. Drug-Induced Liver Injury: Premarketing Clinical Evaluation. 2009.…/Guidances/UCM174090.pdf. Accessed 18 Aug 2014.

  10. 10.

    National Institutes of Health. National Library of Medicine. MedlinePlus. ALT. Accessed 18 Aug 2014.

  11. 11.

    The Merck Manual, Professional Edition. Normal Laboratory Values: Blood, Plasma, and Serum. Accessed 18 Aug 2014.

Download references

Author information



Corresponding author

Correspondence to Elizabeth Barbehenn.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Barbehenn, E., Almashat, S., Carome, M. et al. Hepatotoxicity of Alogliptin. Clin Pharmacokinet 53, 1055–1056 (2014).

Download citation


  • Placebo
  • Fulminant Hepatic Failure
  • Alogliptin
  • Strict Monitoring
  • Potential Hepatotoxicity